Weekly Recap: FDA acceptance, June 29 date and Brokers keep Buy ratings
Unicycive Therapeutics (NASDAQ:UNCY) fixed a third‑party manufacturing problem, resubmitted its FDA filing which was accepted with a June 29, 2026 action date, while brokers remain bullish—B. Riley keeps a $22 target and HC Wainwright trims its target to $15.Previous Week Recap This is…
Unicycive Therapeutics (NASDAQ:UNCY) fixed a third‑party manufacturing problem, resubmitted its FDA filing which was accepted with a June 29, 2026 action date, while brokers remain bullish—B. Riley keeps a $22 target and HC Wainwright trims its target to $15.Previous Week Recap
This is…
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
